The local medical sector is excited with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing impressive results in early trials for treating obesity. This https://listbell.com/story11716887/retatrutide-australia-a-emerging-solution-for-obesity-treatment